68 related articles for article (PubMed ID: 15741747)
21. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
J Hypertens; 1998 Sep; 16(9):1357-69. PubMed ID: 9746123
[TBL] [Abstract][Full Text] [Related]
22. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients.
Gałecki P; Szemraj J; Bieńkiewicz M; Zboralski K; Gałecka E
Hum Psychopharmacol; 2009 Jun; 24(4):277-86. PubMed ID: 19319921
[TBL] [Abstract][Full Text] [Related]
23. Major depressive subtypes and treatment response.
Fava M; Uebelacker LA; Alpert JE; Nierenberg AA; Pava JA; Rosenbaum JF
Biol Psychiatry; 1997 Oct; 42(7):568-76. PubMed ID: 9376453
[TBL] [Abstract][Full Text] [Related]
24. Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/3 receptors in major depressive disorder studied with [11C]raclopride PET.
Hirvonen J; Hietala J; Kajander J; Markkula J; Rasi-Hakala H; Salminen JK; Någren K; Aalto S; Karlsson H
J Psychopharmacol; 2011 Oct; 25(10):1329-36. PubMed ID: 20829308
[TBL] [Abstract][Full Text] [Related]
25. Serum cortisol concentration in patients with major depression after treatment with fluoxetine.
Piwowarska J; Chimiak A; Matsumoto H; Dziklińska A; Radziwoń-Zaleska M; Szelenberger W; Pachecka J
Psychiatry Res; 2012 Aug; 198(3):407-11. PubMed ID: 22429479
[TBL] [Abstract][Full Text] [Related]
26. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
27. Effects of glucocorticoids on plasma catecholamines in depression.
Rupprecht R; Rupprecht M; Rupprecht C; Sofic E; Barocka A; Beck G; Noder M; Riederer P
Psychiatry Res; 1989 Aug; 29(2):187-98. PubMed ID: 2798597
[TBL] [Abstract][Full Text] [Related]
28. Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression.
Ströhle A; Pasini A; Romeo E; Hermann B; Spalletta G; di Michele F; Holsboer F; Rupprecht R
J Psychiatr Res; 2000; 34(3):183-6. PubMed ID: 10867112
[TBL] [Abstract][Full Text] [Related]
29. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients.
Blardi P; de Lalla A; Urso R; Auteri A; Dell'Erba A; Bossini L; Castrogiovanni P
J Clin Psychopharmacol; 2005 Jun; 25(3):262-6. PubMed ID: 15876907
[TBL] [Abstract][Full Text] [Related]
30. [Fluoxetine: relations between plasma concentration and therapeutic effects in 32 patients with major depression and treated with 20 mg/day].
Bourdeaux R; Pannetier P; Younos C; Desor D; Lehr PR; Capolaghi B
Encephale; 1998; 24(1):57-61. PubMed ID: 9559305
[TBL] [Abstract][Full Text] [Related]
31. Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder.
Tan ZL; Bao AM; Zhao GQ; Liu YJ; Zhou JN
Neuro Endocrinol Lett; 2007 Feb; 28(1):28-32. PubMed ID: 17277729
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine.
Gassó P; Rodríguez N; Blázquez A; Monteagudo A; Boloc D; Plana MT; Lafuente A; Lázaro L; Arnaiz JA; Mas S
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():28-34. PubMed ID: 28025020
[TBL] [Abstract][Full Text] [Related]
33. [Copper-zinc superoxide dismutase activity in platelets in patients with depressive disorder treated by fluoxetine--preliminary study].
Gałecka E; Kedziora J; Florkowski A; Gałecki P
Pol Merkur Lekarski; 2007 Mar; 22(129):182-5. PubMed ID: 17682671
[TBL] [Abstract][Full Text] [Related]
34. Relationships between low red blood cell count and clinical response to fluoxetine in depressed elderly patients.
Mentré F; Golmard JL; Launay JM; Aubin-Brunet V; Bouhassira M; Jouvent R
Psychiatry Res; 1998 Dec; 81(3):403-5. PubMed ID: 9925192
[TBL] [Abstract][Full Text] [Related]
35. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.
Maes M; Westenberg H; Vandoolaeghe E; Demedts P; Wauters A; Neels H; Meltzer HY
J Clin Psychopharmacol; 1997 Oct; 17(5):358-64. PubMed ID: 9315986
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory Profiles in Depressed Adolescents Treated with Fluoxetine: An 8-Week Follow-up Open Study.
Pérez-Sánchez G; Becerril-Villanueva E; Arreola R; Martínez-Levy G; Hernández-Gutiérrez ME; Velasco-Velásquez MA; Alvarez-Herrera S; Cruz-Fuentes C; Palacios L; de la Peña F; Pavón L
Mediators Inflamm; 2018; 2018():4074051. PubMed ID: 30662368
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory modulation of fluoxetine use in patients with depression: A systematic review and meta-analysis.
Almeida IB; Gomes IA; Shanmugam S; de Moura TR; Magalhães LS; de Aquino LAG; de Souza Araújo AA; Oliveira PD; Santos MRV
Cytokine; 2020 Jul; 131():155100. PubMed ID: 32315957
[TBL] [Abstract][Full Text] [Related]
38. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.
Sit D; Perel JM; Luther JF; Wisniewski SR; Helsel JC; Wisner KL
J Clin Psychopharmacol; 2010 Aug; 30(4):381-6. PubMed ID: 20631556
[TBL] [Abstract][Full Text] [Related]
39. CCK4-induced panic in healthy subjects II: neurochemical correlates.
Jerabek I; Boulenger JP; Bradwejn J; Drumheller A; Lavallée YJ; Jolicoeur FB
Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):157-64. PubMed ID: 10082242
[TBL] [Abstract][Full Text] [Related]
40. Influence of food intake on concentrations of plasma catecholamines and cortisol.
Knoll E; Müller FW; Ratge D; Bauersfeld W; Wisser H
J Clin Chem Clin Biochem; 1984 Sep; 22(9):597-602. PubMed ID: 6491621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
